Skip to content

Emilie Olié

7 papers in the library · 39 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study)

Therapeutic Advances in Psychopharmacology August 1, 2026 Pierre-Michel Llorca, Anne Sauvaget, Emilie Olié et al.

Background: Major depressive disorder (MDD) is highly prevalent and associated with significant disability and mortality. Treatment-resistant depression (TRD), defined as inadequate response to ⩾2 antidepressant lines, remains a major therapeutic challenge. Esketamine nasal spray, approved in 2019 for TRD, demonstrated efficacy and safety in randomized trials, but real-world evidence remains...

One dose of Psilocybin modulates Brain Activity among Depressive patients : Preliminary Neuroimaging Results from the PSILODAC Study

European Psychiatry June 1, 2026 M. Pastre, F. Pereira, T. Gibert et al.

Introduction Treatment-resistant depression (TRD) remains a major clinical challenge, with limited efficacy of available therapies. Psilocybin, a serotonergic psychedelic, has shown promising antidepressant effects. As recent studies have shown altered default mode network activity following psilocybin administration, further neuroimaging research in clinical populations is needed to clarify...

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

European Journal of Psychotraumatology April 1, 2026 Maud Rothärmel, Lila Mekaoui, François Kazour et al. 1 citation

Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of functional impairment and suicide. Esketamine nasal spray is a recent validated treatment for TRD, but its efficacy on comorbid TRD-PTSD remains...

[Suicidal ideation and behaviors: a transdiagnostic dimension for precision psychiatry].

Medecine sciences : M/S May 1, 2025 Aiste Lengvenyte, Emilie Olié, Marion Leboyer et al.

Suicidal thoughts and behaviors represent a transdiagnostic dimension independent of traditional psychiatric diagnoses. This specificity is supported by genetic studies, biomarkers, and preclinical research on endophenotypes associated with suicidal behaviors, such as impulsivity, anhedonia, and hopelessness. Clear mechanisms involving inflammation, the stress response, the serotonergic system,...

French Translation and Validation of the Ontological Addiction Scale (OAS).

International Journal of Environmental Research and Public Health March 27, 2025 Déborah Ducasse, Martin Leurent, Marie-Christine Picot et al. 1 citation

According to ontological addiction theory, the root cause of mental suffering is a dysfunctional conceptualisation of the self. Typically, an individual with such a flawed self-concept deems themselves to be intrinsically separate from their surroundings, with their beliefs, choices and behaviours structured in order to reinforce their sense of an independently existing self. The Ontological...

Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors

Pharmaceuticals November 24, 2021 Robertas Strumila, Bénédicte Nobile, Laura Korsakova et al. 35 citations

The available interventions for people who are at risk of suicide have limited efficacy. Recently, research on new mental health treatments has started to consider psychedelic compounds, particularly psilocybin, a molecule with a few thousand years of history of use in human societies. The possible effects of psilocybin on suicidal ideation and behaviors have not been specifically studied yet;...